Neuron23 and QIAGEN Announce Collaboration to Develop the First Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug

Collaboration combines leading expertise of Neuron23 in drug discovery, data science, and machine learning with QIAGEN’s long-standing experience in companion diagnostic development SOUTH SAN FRANCISCO, Calif. and GERMANTOWN, Md. and HILDEN, Germany, Sept. 14, 2022 /PRNewswire/ –…